Needham & Company LLC Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals (NASDAQ:IONS) had its price target hoisted by equities research analysts at Needham & Company LLC from $103.00 to $105.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective points to a potential upside of 41.43% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Piper Sandler boosted their price objective on Ionis Pharmaceuticals from $87.00 to $100.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Bank of America raised their target price on Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Morgan Stanley set a $95.00 price target on Ionis Pharmaceuticals and gave the company an “overweight” rating in a report on Wednesday, February 25th. Leerink Partners upped their price target on shares of Ionis Pharmaceuticals from $102.00 to $104.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 3rd. Finally, TD Cowen restated a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $90.15.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS opened at $74.24 on Wednesday. The stock has a market capitalization of $12.26 billion, a P/E ratio of -30.43 and a beta of 0.31. The company has a current ratio of 3.83, a quick ratio of 3.81 and a debt-to-equity ratio of 2.76. Ionis Pharmaceuticals has a 1 year low of $23.95 and a 1 year high of $86.74. The firm has a 50 day moving average of $78.99 and a 200-day moving average of $75.56.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.18). Ionis Pharmaceuticals had a negative return on equity of 68.82% and a negative net margin of 40.36%.The business had revenue of $203.33 million for the quarter, compared to the consensus estimate of $156.07 million. During the same quarter last year, the company earned ($0.66) earnings per share. The firm’s revenue was down 10.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Ionis Pharmaceuticals will post -3.5 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Brett P. Monia sold 34,103 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $75.92, for a total value of $2,589,099.76. Following the transaction, the chief executive officer owned 242,662 shares in the company, valued at $18,422,899.04. This trade represents a 12.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kyle Jenne sold 37,277 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $75.85, for a total value of $2,827,460.45. Following the completion of the sale, the executive vice president owned 11,714 shares of the company’s stock, valued at approximately $888,506.90. The trade was a 76.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 1,035,882 shares of company stock worth $80,492,247. 2.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $25,000. Golden State Wealth Management LLC raised its stake in shares of Ionis Pharmaceuticals by 198.4% during the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after buying an additional 250 shares during the last quarter. Mather Group LLC. bought a new stake in shares of Ionis Pharmaceuticals during the third quarter worth approximately $27,000. Brown Brothers Harriman & Co. acquired a new position in Ionis Pharmaceuticals in the fourth quarter valued at approximately $27,000. Finally, Quarry LP acquired a new position in Ionis Pharmaceuticals in the third quarter valued at approximately $38,000. Institutional investors own 93.86% of the company’s stock.

Key Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Barclays raised its price target to $106 and moved to an “overweight” rating, implying roughly ~43% upside from current levels — a clear catalyst for buying interest. Barclays PT raise (Benzinga)
• Positive Sentiment: 247WallSt summarized Barclays’ bullish thesis (calls for a ~45% move to $106), reinforcing the same positive narrative and helping momentum among growth/biotech investors. Why Barclays Thinks Ionis Is Headed for a 45% Surge
• Positive Sentiment: Needham raised its target to $105 and kept a “buy” rating, adding to the cluster of upward revisions that make the stock appealing to traders chasing analyst-led breakouts. Needham PT raise (Benzinga)
• Positive Sentiment: HC Wainwright boosted its target to $120 and reiterated a Buy, and its analyst also modeled a much improved FY‑2027 EPS (-$0.35 vs. much deeper consensus losses), signaling expectations for near‑term improvement in profitability assumptions. HC Wainwright research note (MarketBeat)
• Positive Sentiment: MSN reports Ionis repriced a drug ahead of a key FDA decision, which the company frames as positioning the therapy for a larger commercial market — a strategic move that could lift revenue assumptions if the FDA outcome is favorable. Ionis repriced drug ahead of FDA decision (MSN)
• Neutral Sentiment: A comparative head‑to‑head writeup vs. Innate Pharma provides market context but doesn’t add a direct catalyst; useful for longer‑term investors researching relative positioning. Head to Head Analysis (AmericanBankingNews)
• Negative Sentiment: Company insider Eugene Schneider sold 5,812 shares — a modest-sized sale that investors may watch for pattern changes but likely not material on its own. Insider sale report (AmericanBankingNews)

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.